Werth et al. Lenabasum phase 3 trial indermatomyositis. Primary endpoint (TIS week 28) not met. Subgroup analysis suggest small effect on muscle and modest effect on skin disease @rheumnow #ACR22 Abstr#0173
Cutaneous Manifestations, Clinical Trials, Safety Efficacy and Safety of Lenabasum in the Phase 3 DeterMine Trial in Dermatomyositis - ACR Meeting Abstracts
